Johns Hopkins Institute for Clinical and Translational Research

约翰·霍普金斯临床与转化研究所

• 批准号: 10398028
• 负责人: Daniel Ernest Ford
• 金额: $ 944.74万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-31 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10398028
• 关键词: Accident and Emergency department; Address; Alzheimer' s Disease; American; Baltimore; Budgets; Clinic; Clinical Research; Collaborations; Communication; Communities; Complex; Conduct Clinical Trials; Consultations; Country; Data; Databases; Diagnosis; Disease; Ecosystem; Engineering; Environment; Funding; Goals; Health; Health Promotion; Health Status; Health system; Healthcare; Healthcare Systems; Home; Hospitalization; Hospitals; Incentives; Individual; Informatics; Information Systems; Institutes; Institution; Insurance; Interdisciplinary Study; Intervention; Joints; Laboratories; Lead; Leadership; Learning; Maryland; Measurable; Medicare; Mentors; Methodology; Mission; Modeling; Multiple Partners; Obesity; Outcome; Pathway interactions; Patients; Pharmacy Schools; Phase; Population; Population Group; Population Heterogeneity; Prevention; Public Health; Randomized Clinical Trials; Research; Research Personnel; Research Support; Research Training; Resources; Safety; Science; Scientist; Services; Sexually Transmitted Diseases; Specialist; Speed; Substance abuse problem; Technology; Training; Training Programs; Translating; Translational Research; Translations; Universities; Vision; Work; care outcomes; clinical infrastructure; drug development; drug discovery; effective therapy; experience; global health; health care availability; health care delivery; health disparity; improved; individual patient; innovation; investigator training; multidisciplinary; next generation; novel therapeutics; patient population; population health; precision medicine; programs; skills; translational scientist; waiver

Contact PD/PI: Ford, Daniel Ernest The Johns Hopkins Institute for Clinical and Translational Research (ICTR) has been a productive, innovative and impactful organization in transforming how clinical and translational research is conducted throughout Johns Hopkins University. Enhancing collaborative research teams, advancing informatics, promoting new methodologies, providing access to regulatory support, and bringing researchers and the community closer together as true partners in discovery have all made translational research more successful. Over the next five years, the Johns Hopkins ICTR will move beyond its current research community to create a comprehensive regional hub that includes new partners – the University of Maryland Baltimore (UMB), Morgan State University (MSU) and Kaiser Permanente Mid-Atlantic States (KPMAS). These partners bring complementary expertise and connections to distinct populations. Together, we have an opportunity to conduct high quality innovative research, and rapidly implement findings that impact the health of our state and region. Building on our extensive connections with community groups, we will move to a new phase of joint governance with bidirectional communication and participation on key ICTR committees. New programs will include a Trial Innovation Unit that will focus on improving methodologic and operational support for research teams conducting randomized clinical trials so that the impact of these trials is enhanced. A goal of this Unit will be to pilot and disseminate approaches that move randomized clinical trials closer to the precision medicine paradigm, with a focus on outcomes of greatest value to individual patients. Combining drug discovery scientists at Johns Hopkins with experts at the UMB School of Pharmacy, the ICTR will create a new Drug Discovery and Development Core. KPMAS and Johns Hopkins will continue to jointly fund programs that push the boundaries of how a Learning Health Care system can improve health outcomes. The ICTR provides a model for training investigators to work in multidisciplinary teams with experienced mentors using the most rigorous methodologies. We will enhance our training programs by incorporating principles of biodesign from the engineering tradition into the experience of all trainees. This places a higher emphasis on identification of the problem, engaging important stakeholders (clinicians, patients, IT professionals) to develop solutions, and identifying the most effective pathways to dissemination. Translational research demands the skills of many professionals working together to address complex problems. The Johns Hopkins ICTR is poised to leverage our current services to benefit new partners who have extensive responsibility for the conduct of research and health care delivery in Maryland. Working together, we expect to have a measurable impact on translational research in Maryland. Page 679 Project Summary/Abstract Contact PD/PI: Ford, Daniel Ernest By identifying and overcoming barriers in the translational pathway, increasing scientific collaboration, providing consultative services, clinical infrastructure, and technology cores that bridge the gap between the laboratory and the clinic, the ICTR helps to speed the pace of scientific discovery, bringing effective therapies to the public, and ultimately improving the health of Americans. Page 680

联系PD/PI：福特，丹尼尔·欧内斯特 约翰·霍普金斯临床与转化研究研究所（ICTR）是一种创新的产品 以及有影响力的组织，以改变整个过程中的临床和翻译研究方式 约翰·霍普金斯大学。加强协作研究团队，推进信息，促进新的 方法，提供监管支持的访问以及使研究人员和社区更加紧密 作为发现的真正合作伙伴，这一切都使翻译研究变得更加成功。在接下来的五个 多年来，约翰·霍普金斯（Johns Hopkins）ICTR将超越其当前的研究社区，以创造一个全面的 包括新合作伙伴的区域枢纽 - 马里兰州巴尔的摩大学（UMB），摩根州立大学 （MSU）和Kaiser Permanente中大西洋国家（KPMAS）。这些合作伙伴带来完整的专业知识 和与不同人群的联系。我们在一起有机会进行高质量的创新 研究并迅速实施影响我们州和地区健康的发现。建立在我们的基础上 与社区团体的广泛联系，我们将与 双向交流和关键ICTR委员会的参与。新计划将包括试用 创新单位将着重于改善研究团队的方法论和运营支持 进行随机临床试验，以增强这些试验的影响。该单元的目标是 飞行员和传播方法将随机临床试验移动到更接近精度医学 范式，重点是对个别患者的最大价值结果。结合药物发现 约翰·霍普金斯（Johns Hopkins）的科学家与UMB药学院的专家一起，ICTR将创建一种新药 发现与发展核心。 KPMA和Johns Hopkins将继续共同资助推动计划 学习保健系统如何改善健康成果的界限。 ICTR提供了 培训调查人员在多学科团队中与经验丰富的导师一起工作的模型 严格的方法。我们将通过纳入生物设计原则来增强我们的培训计划 工程传统进入了所有受训者的经验。这更加重视对 这个问题是吸引重要的利益相关者（临床医生，患者，IT专业人员）开发解决方案，并 确定最有效的传播途径。翻译研究需要许多人的技能 专业人士共同努力解决复杂问题。约翰·霍普金斯·伊克特（John Hopkins ICTR）被中毒以利用 我们目前的服务受益于对研究进行广泛责任的新合伙人的服务 马里兰州的医疗保健提供。共同努力，我们希望对翻译产生可衡量的影响 马里兰州的研究。 第679页 项目摘要/摘要 联系PD/PI：福特，丹尼尔·欧内斯特 通过识别和克服转化途径中的障碍，增加科学合作， 提供咨询服务，临床基础设施和技术核心，这些核心弥合 实验室和诊所，ICTR有助于加快科学发现的空间，带来有效的疗法 向公众来说，最终改善了美国人的健康。 第680页